Trial · NCT01705977
Results by group42
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 42
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Deaths - On Treatment Period (Week 52) | Placebo | 8 | Participants | ||
| Number of Deaths - On Treatment Period (Week 52) | Belimumab 10 mg/kg | 10 | Participants | ||
| Number of Participants Who Reported Protocol Defined Adverse Events of Special Interest (AESI): On-treatment Period (Week 52) | Placebo | Serious Infections, n=2001, 2002 | 82 | Participants | |
| Number of Participants Who Reported Protocol Defined Adverse Events of Special Interest (AESI): On-treatment Period (Week 52) | Belimumab 10 mg/kg | Serious Infections, n=2001, 2002 | 75 | Participants | |
| Number of Participants Who Reported Protocol Defined Adverse Events of Special Interest (AESI): On-treatment Period (Week 52) | Placebo | Opportunistic Infections and Other Infections of Interest, n=2001, 2002 | 50 | Participants | |
| Number of Participants Who Reported Protocol Defined Adverse Events of Special Interest (AESI): On-treatment Period (Week 52) | Belimumab 10 mg/kg | Opportunistic Infections and Other Infections of Interest, n=2001, 2002 | 36 | Participants | |
| Number of Participants Who Reported Protocol Defined Adverse Events of Special Interest (AESI): On-treatment Period (Week 52) | Placebo | Malignancies (Excluding NMSC), n=2001, 2002 | 5 | Participants | |
| Number of Participants Who Reported Protocol Defined Adverse Events of Special Interest (AESI): On-treatment Period (Week 52) | Belimumab 10 mg/kg | Malignancies (Excluding NMSC), n=2001, 2002 | 5 | Participants | |
| Number of Participants Who Reported Protocol Defined Adverse Events of Special Interest (AESI): On-treatment Period (Week 52) | Placebo | NMSC, n=2001, 2002 | 3 | Participants | |
| Number of Participants Who Reported Protocol Defined Adverse Events of Special Interest (AESI): On-treatment Period (Week 52) | Belimumab 10 mg/kg | NMSC, n=2001, 2002 | 4 | Participants | |
| Number of Participants Who Reported Protocol Defined Adverse Events of Special Interest (AESI): On-treatment Period (Week 52) | Placebo | Psychiatric Events Suggesting Serious Mood Disorders and Anxiety (Serious depression), n=2001, 2002 | 1 | Participants | |
| Number of Participants Who Reported Protocol Defined Adverse Events of Special Interest (AESI): On-treatment Period (Week 52) | Belimumab 10 mg/kg | Psychiatric Events Suggesting Serious Mood Disorders and Anxiety (Serious depression), n=2001, 2002 | 7 | Participants | |
| Number of Participants Who Reported Protocol Defined Adverse Events of Special Interest (AESI): On-treatment Period (Week 52) | Placebo | Suicidality (C-SSRS), n=1986, 1972 | 23 | Participants | |
| Number of Participants Who Reported Protocol Defined Adverse Events of Special Interest (AESI): On-treatment Period (Week 52) | Belimumab 10 mg/kg | Suicidality (C-SSRS), n=1986, 1972 | 28 | Participants | |
| Number of Participants Who Reported Protocol Defined Adverse Events of Special Interest (AESI): On-treatment Period (Week 52) | Placebo | SIHR, n=2001, 2002 | 2 | Participants | |
| Number of Participants Who Reported Protocol Defined Adverse Events of Special Interest (AESI): On-treatment Period (Week 52) | Belimumab 10 mg/kg | SIHR, n=2001, 2002 | 8 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs) Reported During On-treatment Period (Week 52) | Placebo | 222 | Participants | ||
| Number of Participants With Serious Adverse Events (SAEs) Reported During On-treatment Period (Week 52) | Belimumab 10 mg/kg | 220 | Participants | ||
| Number of Deaths Reported - On-study Period (Week 52) | Placebo | 22 | Participants | ||
| Number of Deaths Reported - On-study Period (Week 52) | Belimumab 10 mg/kg | 13 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01705977/results